Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

New data from Eli Lilly (LLY) showed Omvoh-treated patients with moderately to severely active ulcerative colitis and bowel ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

Eli Lilly has reported that its interleukin-13 (IL-13) inhibitor Ebglyss (lebrikizumab-lbkz) showed sustained skin clearance ...

Eli Lilly's experimental weight-loss pill, orforglipron, has met key FDA criteria for an expedited review, boosting its ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for ...

Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and ...

CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...

The investment, which will expand Eli Lilly’s existing campus in Puerto Rico, is slated to create 100 new jobs, on top of ...

In its mission to enlighten others to the symptoms of obstructive sleep apnea (OSA), Eli Lilly is getting an assist from NBA ...